Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Sales and Divestitures (2017 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $152000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 24.59% year-over-year to $152000.0, compared with a TTM value of $152000.0 through Sep 2025, up 24.59%, and an annual FY2025 reading of $152000.0, up 24.59% over the prior year.
  • Gains from Sales and Divestitures was $152000.0 for Q3 2025 at Enanta Pharmaceuticals, up from $68000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $152000.0 in Q3 2025 and bottomed at $18000.0 in Q3 2022.
  • Average Gains from Sales and Divestitures over 5 years is $72352.9, with a median of $56000.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures soared 1400.0% in 2021, then crashed 60.0% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $29000.0 in 2021, then skyrocketed by 93.1% to $56000.0 in 2022, then soared by 107.14% to $116000.0 in 2023, then rose by 24.14% to $144000.0 in 2024, then increased by 5.56% to $152000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ENTA at $152000.0 in Q3 2025, $68000.0 in Q2 2025, and $145000.0 in Q1 2025.